CASE CCC IN THE NEWS
High-Risk MDS: RIC Transplant Shown as OK for Older Patients
Oncology Times - Aug 10, 2013
Older patients with higher-risk myelodysplastic syndromes (MDS) may well benefit from reduced-intensity conditioning (RIC) allogeneic hematopoietic stem-cell transplantation, according to data showing a survival benefit in a study from Dana-Farber Cancer Institute... Mikkael A. Sekeres, MD, MS, [Oncology Times'] Clinical Advisory Editor for Hematology/Oncology, who is Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Center and Chair of the Hematology/Oncology Pharmacy and Therapeutics Committee, also thought the data may have an impact on CMS policy: "The study is timely because CMS is finally paying for transplants for MDS, but only under approved transplant protocols," he said.
A Doctor in the Family
New York Times - Aug 8, 2013
Dr. Mikkael Sekeres shares his personal story of dealing with family health issues as a medical professional.
Blood Pressure Meds Linked to Raised Breast Cancer Risk
CBS News - Aug 5, 2013
Taking calcium channel blockers for years may raise a woman's risk for breast cancer, new research published Aug. 5 in JAMA Internal Medicine shows...Dr. Halle Moore, a breast oncologist at the Cleveland Clinic, told CBSNews.com that some risk factors for breast cancer, like family history, are not modifiable, but this study points to a potential risk factor that may be. However, she emphasized more research is needed to confirm this link...
Department Interview with Neal Meropol
CWRU Department of Medicine eNewsletter - Summer 2013
Neal Meropol, MD, Hematology & Oncology Division Chief, discusses the impact of the Affordable Care Act on clinical trials, shares his insight on effective doctor-patient communication and gives his thoughts on critical issues in cancer health care.
Publication Support Acknowledgement
Please remember to acknowledge the valuable support provided by the Cancer Center and its core facilities in your research papers and publications:
"This research was supported by the Case Comprehensive Cancer Center (P30CA043703)." OR
"This research was supported by the [insert facility name] Core Facility of the Case Comprehensive Cancer Center (P30CA043703)."
Lung Cancer Biospecimen Resource Network
The Lung Cancer Biospecimen Resource Network (LCBRN) is an open access biorepository that provides specimens to academic and private industry scientists worldwide. The LCBRN obtains tissue and biofluid samples from lung cancer patients for use in biomedical research. Subjects voluntarily donate tissue, bronchial lavage fluid, blood, urine and saliva, and have all signed informed consent documents allowing the use of their samples in research.
A network of three academic medical centers comprise the LCBRN: Medical University of South Carolina, University of Virginia, and Washington University in St. Louis. Biospecimens are collected at these sites according to standard operating procedures and are shipped to the LCBRN Coordination Center at University of Virginia for storage.
Researchers desiring material from the LCBRN must have local approval to work with coded-linked human biospecimens, must submit an application for review by the LCBRN Scientific Review Panel, and must have institutional approval for the provisions in the LCBRN investigator agreement.
ASCO Special Awards Program
Each year, through its Special Awards Program, the American Society of Clinical Oncology (ASCO) recognizes researchers, patient advocates, and leaders of the global oncology community who have made significant contributions to enhancing cancer care. Recipients of ASCO's highest, most prestigious awards collectively represent those who have made significant strides in cancer care and treatment and who have shown outstanding leadership in the oncology community. Please take this opportunity to nominate a colleague for the 2014 ASCO Special Awards, open nowthrough August 26. You will need your ASCO.org username and password to log-in to nominate.
This year, ASCO added the Excellence in Teaching Award to its roster of Special Awards. This new Award will be presented to an ASCO member who has had a demonstrable impact on their trainees (residents, postdoctoral fellows, and/or clinical fellows) and who has inspired and shaped the trainee's practice of cancer medicine.
The 2014 Special Awards are as follows:
- American Cancer Society Award and Lecture
- B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
- David A. Karnofsky Memorial Award and Lecture
- Distinguished Achievement Award
- Excellence in Teaching Award
- Gianni Bonadonna Breast Cancer Award and Lecture
- Humanitarian Award
- Partners in Progress Award
- Pediatric Oncology Award and Lecture
- Public Service Award
- Science of Oncology Award and Lecture
- Special Recognition Award
ASH Bridge Grant Program
In 2013 and for the next two years, American Society of Hematology (ASH) new bridge grant program will provide at least 30 one-year awards annually to ASH members who applied for an NIH R01 grant or equivalent but were denied funding due to budget cutbacks. The long-term goal of the award is to help sustain recipients' research and contribute to their retention in hematology investigation. Dr. Yu-Yung Yang was one of 17 scientists to receive funding as part of the first round of the awards earlier this year.
Deadline: November 1